A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Angiotensin Receptor Antagonists
/ adverse effects
Angiotensin-Converting Enzyme Inhibitors
/ adverse effects
Animals
Betacoronavirus
COVID-19
Consensus
Coronavirus Infections
/ complications
Humans
Hypertension
/ complications
Models, Animal
Pandemics
Peptidyl-Dipeptidase A
/ drug effects
Pneumonia, Viral
/ complications
SARS-CoV-2
Journal
The New Zealand medical journal
ISSN: 1175-8716
Titre abrégé: N Z Med J
Pays: New Zealand
ID NLM: 0401067
Informations de publication
Date de publication:
03 04 2020
03 04 2020
Historique:
entrez:
4
4
2020
pubmed:
4
4
2020
medline:
10
4
2020
Statut:
epublish
Résumé
There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-87Déclaration de conflit d'intérêts
Nil.